Celldex Therapeutics, Inc. (CLDX) Cash Flow Statement
Where CLDX’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$210.9M
- Capital expenditures
- $2.7M 180.9% of revenue
- Free cash flow
- −$213.7M −14,243.9% margin
- Returned to shareholders
- —
- Change in cash
- $515,000 cash at year-end $28.9M
Cash from operations
−$210.9M
Capital expenditures
−$2.7M
Investments (net)
+$211.8M
Other financing
+$2.4M
Change in cash
$515,000
Drawn to scale: where the cash came from and how it was used. Hover for values.
CLDX operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
CLDX cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$113.0M2016 | −$210.9M2025 | — | |
| Capital expenditures | $2.8M2016 | $2.7M2025 | −0.2%/yr | |
| Free cash flow | −$115.8M2016 | −$213.7M2025 | — | |
| Free cash flow margin | −1,706.3%2016 | −14,243.9%2025 | −12,537.7 pts | |
| Stock-based compensation | $15.3M2016 | $36.2M2025 | +10.0%/yr | |
| Dividends paid | $02016 | $02017 | — | |
| Share buybacks (net) | $02016 | $02021 | — | |
| Capex / revenue | 40.5%2016 | 180.9%2025 | +140.4 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
CLDX cash flow by activity
OperatingInvestingFinancingChange in cash
CLDX net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
CLDX cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$258.8M | −$157.9M | −$141.4M | −$112.3M | −$70.5M | −$59.8M | −$50.9M | −$151.2M | −$93.0M | −$128.5M |
| Depreciation & amortization | $3.4M | $3.2M | $3.0M | $2.9M | $3.1M | $3.9M | $4.9M | $3.8M | $5.3M | $4.1M |
| Stock-based compensation | $36.2M | $34.2M | $23.9M | $15.6M | $9.0M | $3.9M | $4.6M | $8.1M | $12.3M | $15.3M |
| Change in working capital | $14.1M | −$21.6M | $13.5M | −$3.9M | −$1.1M | −$299,000 | −$4.3M | −$15.4M | −$12.2M | −$6.6M |
| Other non-cash items | −$5.8M | −$15.7M | −$6.2M | −$6.0M | −$1.4M | $11.8M | −$623,000 | $79.4M | −$12.3M | $2.6M |
| Cash from operating activities | −$210.9M | −$157.8M | −$107.3M | −$103.7M | −$60.9M | −$40.4M | −$46.4M | −$75.2M | −$99.9M | −$113.0M |
| Investing activities | ||||||||||
| Capital expenditures | −$2.7M | −$1.9M | −$1.8M | −$1.8M | −$1.2M | −$1.6M | −$731,000 | −$813,000 | −$1.8M | −$2.8M |
| Investments (net) | $211.8M | −$290.1M | −$105.8M | $89.9M | −$214.9M | −$98.2M | $17.8M | $30.3M | $48.3M | $67.1M |
| Acquisitions & other investing | $0 | $1.9M | $1.8M | $1.8M | $27,000 | $1.6M | $20,000 | $342,000 | $0 | $4.6M |
| Cash from investing activities | $209.1M | −$290.1M | −$105.8M | $89.9M | −$216.2M | −$98.2M | $17.1M | $29.8M | $46.5M | $68.9M |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share repurchases & issuance (net) | — | — | — | — | $272.4M | $171.2M | $16.3M | $29.4M | $51.3M | $14.5M |
| Net borrowing (repayment) | — | — | — | $0 | $0 | — | — | — | — | — |
| Shares issued | $0 | $432.3M | $216.2M | $0 | $269.9M | $170.8M | $16.2M | $29.0M | $0 | $0 |
| Other financing | $2.4M | $9.2M | $2.2M | $4.1M | −$269.9M | −$170.8M | −$16.2M | −$29.0M | $0 | $0 |
| Cash from financing activities | $2.4M | $441.4M | $218.5M | $4.1M | $272.4M | $171.2M | $16.3M | $29.4M | $51.3M | $14.5M |
| Summary | ||||||||||
| Net change in cash | $515,000 | −$6.5M | $5.4M | −$9.7M | −$4.7M | $32.6M | −$13.1M | −$16.0M | −$2.2M | −$29.6M |
| Cash at end of period | $28.9M | $28.4M | $34.8M | $29.4M | $39.1M | $43.8M | $11.2M | $24.3M | $40.3M | $42.5M |
| Free cash flow | −$213.7M | −$159.7M | −$109.1M | −$105.6M | −$62.2M | −$42.0M | −$47.1M | −$76.0M | −$101.7M | −$115.8M |
| Free cash flow margin | −14,243.9% | −2,274.9% | −1,585.2% | −4,478.6% | −1,336.4% | −565.6% | −1,319.5% | −797.3% | −798.2% | −1,706.3% |
| Capex / revenue | 180.9% | 27.3% | 26.4% | 77.6% | 26.9% | 20.9% | 20.5% | 8.5% | 14.0% | 40.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$73.5M | −$78.7M | −$81.3M | −$67.0M | −$56.6M | −$53.8M | −$47.1M | −$42.1M | −$35.8M | −$32.8M | −$43.3M | −$38.3M |
| Depreciation & amortization | $902,000 | $854,000 | $816,000 | $824,000 | $873,000 | $867,000 | $819,000 | $786,000 | $797,000 | $775,000 | $759,000 | $767,000 |
| Stock-based compensation | $8.4M | $8.5M | $8.9M | $8.8M | $9.2M | $9.3M | $9.8M | $9.6M | $7.6M | $7.2M | $7.2M | $7.1M |
| Change in working capital | $8.5M | $4.3M | $8.5M | $9.8M | $4.2M | −$8.5M | $7.4M | −$19.3M | $2.8M | −$12.5M | $5.0M | $13.0M |
| Other non-cash items | −$1.7M | −$627,000 | −$882,000 | −$1.0M | −$1.7M | −$2.3M | −$3.4M | −$4.3M | −$4.7M | −$3.3M | −$2.2M | −$1.6M |
| Cash from operating activities | −$57.4M | −$65.6M | −$63.9M | −$48.6M | −$44.0M | −$54.4M | −$32.5M | −$55.3M | −$29.3M | −$40.6M | −$32.5M | −$19.0M |
| Investing activities | ||||||||||||
| Capital expenditures | −$3.2M | −$1.6M | −$993,000 | −$440,000 | −$728,000 | −$265,000 | −$756,000 | −$618,000 | −$274,000 | −$344,000 | −$666,000 | −$157,000 |
| Investments (net) | −$252.3M | $73.8M | $56.7M | $60.8M | $49.9M | $43.0M | $24.0M | $47.8M | −$46.7M | −$315.2M | −$171.2M | $11.6M |
| Acquisitions & other investing | $0 | $0 | −$288,000 | $440,000 | $728,000 | $265,000 | $756,000 | $618,000 | $274,000 | $344,000 | $666,000 | $157,000 |
| Cash from investing activities | −$255.5M | $72.1M | $55.4M | $60.8M | $49.9M | $43.0M | $24.0M | $47.8M | −$46.7M | −$315.2M | −$171.2M | $11.6M |
| Financing activities | ||||||||||||
| Shares issued | $323.8M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $432.3M | $0 | $0 |
| Other financing | $825,000 | $327,000 | $1.3M | $774,000 | $63,000 | $202,000 | $386,000 | $1.2M | $3.7M | $3.8M | $217.4M | $257,000 |
| Cash from financing activities | $324.7M | $327,000 | $1.3M | $774,000 | $63,000 | $202,000 | $386,000 | $1.2M | $3.7M | $436.1M | $217.4M | $257,000 |
| Summary | ||||||||||||
| Net change in cash | $11.7M | $6.9M | −$7.2M | $13.0M | $5.9M | −$11.2M | −$8.0M | −$6.3M | −$72.3M | $80.3M | $13.7M | −$7.1M |
| Cash at end of period | $47.5M | $35.7M | $28.9M | $36.0M | $23.0M | $17.1M | $28.4M | $36.4M | $42.7M | $115.1M | $34.8M | $21.1M |
| Free cash flow | −$60.6M | −$67.2M | −$64.9M | −$49.1M | −$44.7M | −$54.6M | −$33.2M | −$54.7M | −$29.6M | −$41.0M | −$33.2M | −$19.1M |
| Free cash flow margin | −275,404.5% | −448,180.0% | −86,577.3% | — | −6,127.8% | −7,861.4% | −2,828.3% | −1,714.8% | −1,185.0% | −26,270.5% | −803.7% | −1,262.4% |
| Capex / revenue | 14,450.0% | 10,926.7% | 1,324.0% | — | 99.7% | 38.1% | 64.3% | 19.4% | 11.0% | 220.5% | 16.1% | 10.3% |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
CLDX cash generation
In fiscal 2025 (ended December 31, 2025), Celldex Therapeutics generated -$210.9 million of cash from operations and spent $2.7 million on capital expenditures, leaving free cash flow of -$213.7 million, −14,243.9% of revenue. Cash and equivalents rose by $0.5 million over the year.
Related: CLDX income statement, CLDX balance sheet. See the CLDX stock overview for the latest quote and news.
CLDX cash flow FAQ
What is Celldex Therapeutics's free cash flow?
Celldex Therapeutics's free cash flow was -$213.7 million in fiscal 2025: -$210.9 million of operating cash flow minus $2.7 million of capital expenditures It was -$159.7 million a year earlier..
How much cash does Celldex Therapeutics generate from operations?
Celldex Therapeutics generated -$210.9 million of cash from operating activities in fiscal 2025.
How much does Celldex Therapeutics spend on capital expenditures?
Celldex Therapeutics spent $2.7 million on capital expenditures in fiscal 2025, 180.9% of revenue, compared with $1.9 million the year before.